SO
Therapeutic Areas
Humacyte Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Symvess™ (Acellular Tissue Engineered Vessel) | Vascular Trauma Repair | Approved |
| Acellular Tissue Engineered Vessel (ATEV/HAV) | Arteriovenous (AV) Access for Hemodialysis | Phase 3 |
| BioVascular Pancreas™ | Type 1 Diabetes | Preclinical |
| Lung | Lung Disease / Replacement | Preclinical |
| Urinary Conduit | Urinary Diversion | Preclinical |
| Tracheal Replacement | Tracheal Defects/Disease | Preclinical |
| Esophageal Replacement | Esophageal Defects/Disease | Preclinical |
Leadership Team at Humacyte
LE
Laura E. Niklason, M.D., Ph.D.
Founder, President, Chief Executive Officer
DS
Dale Sander
Chief Corporate Development Officer, Chief Financial Officer & Treasurer
SP
Shamik Parikh, M.D.
Chief Medical Officer
LM
Lisa Molyneux
Executive Vice President, Enterprise Planning & Analysis
HC
Heather Connelly, Ph.D.
Executive Vice President, Regulatory Affairs & Quality